

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Meibomian gland dysfunction and primary Sjögren's syndrome dry eye: a protocol for systematic review and meta-analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-048336
Article Type:	Protocol
Date Submitted by the Author:	22-Dec-2020
Complete List of Authors:	Zi, Changyan; Chengdu University of Traditional Chinese Medicine, huang, qun; Chengdu University of Traditional Chinese Medicine Affiliated Hospital, Ophthalmology Ren, Yuan; Chengdu University of Traditional Chinese Medicine Yao, Huan; Chengdu University of Traditional Chinese Medicine He, Tingting; Chengdu University of Traditional Chinese Medicine Gao, Yongxiang; Chengdu University of Traditional Chinese Medicine, drgaoyx@cdutcm.edu.cn
Keywords:	RHEUMATOLOGY, OPHTHALMOLOGY, Protocols & guidelines < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, IMMUNOLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4 Meibomian gland dysfunction and primary Sjögren's syndrome dry eye: a protocol
5
6 for systematic review and meta-analysis
7
8

9 Changyan Zi,MD¹, Qun Huang,MM³, Yuan Ren,MD², Huan Yao,MD², Tingting
10
11 He,MD², Yongxiang Gao,MD⁴
12
13

14
15 ¹Department of Rheumatology, Hospital of Chengdu University of Traditional Chinese
16
17 Medicine, Chengdu, 610072,China.
18

19
20
21 ² College of Clinical Medicine, Chengdu University of Traditional Chinese Medicine,
22
23 Chengdu,611137, China
24

25
26
27 ³Department of Ophthalmology, Hospital of Chengdu University of Traditional
28
29 Chinese Medicine, Chengdu, 610072,China.
30

31
32
33 ⁴College of International Education of Chengdu University of Traditional Chinese
34
35 Medicine, Chengdu, 610072,China.
36

37
38
39 Corresponding author: Yongxiang Gao, College of International Education of Chengdu
40
41 University of Traditional Chinese Medicine, No.37 Shi-er-qiao Road, Chengdu 610075,
42
43 Sichuan Province, PR China (e-mail:drgaoyx@cductcm.edu.cn)
44

45
46
47 Word count: 1129 words.
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Introduction: Primary Sjögren's syndrome (pSS) is a systematic autoimmune disorder that primarily affects exocrine glands like lacrimal and salivary glands. Dry eye disease is one of the most prevalent manifestations of pSS. Sjögren's syndrome dry eye (SSDE) is generally described as aqueous-deficient dry eye. As leading pathophysiological mechanism of evaporative dry eye, meibomian gland dysfunction (MGD) also has influence on SSDE presented in the latest studies. We speculate that SSDE is more than aqueous-deficient dry eye. Due to lack of evidence-based association of MGD with SSDE, we will conduct a systematic review and meta-analysis to derive a better estimation of the connection, and investigate whether MGD has relationship with the severity of SSDE.

Methods and analysis: The Preferred Reporting items for Systematic Reviews and Meta-Analysis for Protocols (PRISMA-P) 2015 statement was used to implement this protocol. PubMed, Embase, Web of Science, Cochrane Database, China National Knowledge Infrastructure, Wan Fang database will be searched from their inception to 30 April 2021 with restriction of publications in English or Chinese. Two reviewers will independently carry out data extraction and quality assessment. Quality of included studies will be judged by the Newcastle-Ottawa Quality Scale (NOS). We will carry out this meta-analysis via RevMan V.5.4.1. The odds ratio (OR) with 95% confidence interval (CI) will be contained as primary outcome.

Ethics and dissemination: Ethical approval is not required since this meta-analysis is performed based on the published studies. The results will be published in a peer-reviewed journal.

PROSPERO registration number: PROSPERO submission under review.

Strengths and limitations of this study

- ▶ This is the first systematic review and meta-analysis to evaluate the relationship between meibomian gland dysfunction and primary Sjögren's syndrome dry eye.
- ▶ Different types of design, diagnostic criteria of pSS, and various evaluation tools of MGD and DED will give a limit to this study, which may restrict quality of the evidence.
- ▶ Subgroup analysis may decrease these restrictions.

INTRODUCTION

Primary Sjögren's syndrome (pSS) is a female dominated, systematic autoimmune disorder characterized by a widely clinical manifestations ranging from exocrine glands symptoms to extraglandular involvements. Prevalence of pSS is the second highest among rheumatic diseases, next to Rheumatoid Arthritis. As a systematic disease, multidisciplinary cooperation is required, especially department of rheumatology and ophthalmology. Dry eye disease (DED) is usually classified into aqueous-deficient dry eye due to lack of tear secretion and evaporative dry eye which results from tear evaporating too quickly.¹ The mechanism of Sjögren's syndrome dry eye (SSDE) currently remains unclear. In the majority of literatures, SSDE is described as aqueous-deficient dry eye.²⁻⁵ The focus of SSDE turns from pathophysiology of lacrimal glands to eye lids in recent researches,⁶ which is stated that meibomian gland dysfunction (MGD) is responsible for SSDE as well.

The International Workshop on Meibomian Gland Dysfunction defines MGD as a chronic, diffuse abnormality of meibomian glands that is commonly characterized by terminal duct obstruction or qualitative or quantitative changes in glandular secretion.⁶ As leading pathophysiological mechanism of evaporative dry eye,⁷ MGD causes a lesion to tear film lipid layer, and increased tear evaporation and tear hyperosmolarity have been observed, eventually giving rise to onset of dry eye.⁸

To date, assessment for severity of dry eye in pSS has no recognized standards.⁹ Symptoms and signs/tests of tear function are included to evaluate it.¹⁰ Nevertheless, there is a discordance between symptoms and signs in SSDE.¹¹ Currently, proofs have been illustrated that MGD also has influence on SSDE.¹²⁻¹⁵ On the basis of these premises, we speculate that SSDE is more than aqueous-deficient dry eye. Owing to lack of evidence-based association of MGD with SSDE, we will conduct a systematic review and meta-analysis to derive a better estimation of the connection, and investigate whether MGD has relationship with the severity of SSDE.

METHODS

Registration

This protocol has been registered on the PROSPERO on the 13/12/2020. The Preferred Reporting items for Systematic Reviews and Meta-Analysis for Protocols (PRISMA-P) 2015 statement was used to perform this protocol.¹⁶

Patient and public involvement

No patient is involved in this study.

Search strategy

PubMed, Embase, Web of Science, Cochrane Database, China National Knowledge Infrastructure, Wan Fang database will be searched from their inception to 30 April 2021 by two reviewers (TH and YR) independently. Combination of Medical Subject Headings (MeSH) and free terms are utilized to search for potentially qualified publications (Table 1). Reference lists of original and review articles will be screened manually.

Table 1 Search strategy of PubMed
Search items
#1 "Sjogren's Syndrome" OR "Sjogrens Syndrome" OR "Syndrome, Sjogren's" OR "Sjogren Syndrome" OR "Sicca Syndrome" OR "Syndrome, Sicca"
#2 "Meibomian Gland Dysfunction" OR "Dysfunction, Meibomian Gland" OR "Meibomian Gland Dysfunctions" OR "MG Dysfunction" OR "MG Dysfunctions"
#3 #1 AND #2
#4 "Dry Eye Syndromes" OR "Dry Eye Syndrome" OR "Dry Eye Disease" OR "Dry Eye Diseases" OR "Dry Eye" OR "Dry Eyes" OR "Evaporative Dry Eye Disease" OR "Evaporative Dry Eye Syndrome" OR "Evaporative Dry Eye" OR "Dry Eye, Evaporative" OR "Evaporative Dry Eyes"
#5 #3 AND #4

Eligibility criteria

Study design

1
2
3
4 prospective and retrospective cohort studies, case-control studies published in English or Chinese
5 will be incorporated in this meta-analysis. In case of similar essays delivered by the same author in
6 different journals, the latest or study with the largest number of participants will be included.
7
8
9

10 Participants

11
12
13
14 The patients with clinical diagnosed pSS connected with dry eye and meibomian gland dysfunction
15 will be involved, regardless of age, gender and race. The diagnosis of pSS will meet standard
16 diagnostic criteria, such as ACR/EULAR or AECG(no matter what edition it is). For lack of a
17 diagnostic gold standard of MDG and DED currently,¹⁷⁻¹⁸ appraisalment of them is based on
18 evaluation tools made by specialists.
19
20
21
22
23

24 Outcome

25
26
27
28 The primary outcome defining association of MGD and SSDE is incident of meibomian gland
29 dysfunction in SSDE patients. The secondary outcomes estimating the severity of SSDE are tear-
30 film break up time (BUT), Schirmer I test, corneal fluorescein staining(CFS) and ocular surface
31 disease index (OSDI).
32
33
34
35
36

37 Study selection and data extraction

38 Study selection

39
40
41
42
43
44 Two reviewers(TH and YR) will independently conduct study selection. Initial screening of
45 literatures is based on title and abstract to eliminate that cannot meet the inclusion criteria. During
46 the process of full-text screening, all potentially eligible studies will be retrieved for inclusion. Any
47 disagreement will be resolved by discussion. Consulting a third reviewer(YG) to reach a consensus
48 if an agreement still cannot be reached by discussion. The study selection process is demonstrated
49 in a PRISMA flow diagram (figure 1). Literatures meet the standards will be imported into Endnote
50 X9.
51
52
53
54
55
56
57

58 Data extraction

1
2
3
4 The detailed data extracted in an excel spreadsheet by two researchers(HY and QH) and checked
5 for accuracy by YG are as follows: first author's name, year of publication, country of publication,
6 study design, sample size, age, gender, duration of pSS, duration of follow-up, diagnostic criteria,
7 evaluation tools of MGD and DED, outcomes, quality assessment (Newcastle–Ottawa Scale).
8
9
10
11 Authors of primary studies will be contacted to obtain missing data.
12
13

14 **Quality assessment**

15
16
17
18 Quality of contained studies will be estimated by two reviewers (HY and QH) with the Newcastle-
19 Ottawa Quality Scale (NOS) adapted for observational studies. The scale awards 0-9 star based on
20 the selection, comparability and outcome(cohort) or exposure(case-control). Studies with 0-3 stars,
21 4-6 stars, or 7-9 stars are considered as a low-, moderate-, or high-quality. Controversies between
22 two reviewers will be settled by discussion or consulting YG.
23
24
25
26
27
28

29 **Data synthesis and statistical analysis**

30
31
32 At least 5 studies of same outcomes in similar populations will be pooled to perform the meta-
33 analysis by RevMan V.5.4.1. Otherwise, a systematic review will be implemented. For categorical
34 variables, the odds ratio (OR) with 95% confidence interval (CI) will be selected from publications
35 contained or could be calculated from original data. For continuous variables, standard mean
36 difference (SMD) with 95%CI will be obtained.
37
38
39
40
41
42

43 **Assessment of heterogeneity**

44
45
46 Chi-square statistic and the I^2 test are utilized to estimate the statistical heterogeneity among
47 included studies. $P \leq 0.1$ is considered as representative of statistically heterogeneity.¹⁹ I^2 values of
48 $<25\%$, $25\%-50\%$ and $>50\%$ representing low, medium and high heterogeneity.²⁰ For a significant
49 heterogeneity($I^2 \geq 50\%$, $P < 0.1$), a random-effect model will be selected to synthesize the data.
50
51
52
53
54
55
56
57
58
59
60
Otherwise, a fixed effect model will be used.

60 **Subgroup analysis**

1
2
3
4 Subgroup analysis is applied to high heterogeneity among publications included with following
5 aspects, such as age, sex, diagnostic criteria for pSS, study design, different evaluation tools of
6 MGD and DED.
7
8
9

10 **Sensitivity analysis**

11
12
13
14 Eliminating literatures one by one to conduct sensitivity analysis, possible major source of
15 heterogeneity may be found.
16
17

18 **Assessment of publication bias**

19
20
21
22 Visual assessment of the funnel plot will be applied to appraise publication bias if more than 10
23 articles contained.²¹
24
25

26 **Quality of evidence**

27
28
29
30 The Grading of Recommendations Assessment, Development and Evaluation(GRADE) will be
31 used to assess the strength evidence for each outcome, which will be divided into high, moderate,
32 low and very low level.²²
33
34
35
36
37

38 **Ethics and dissemination**

39
40
41 Ethical approval is not required since this meta-analysis is performed based on the published studies.
42
43 The results will be published in a peer-reviewed journal.
44
45

46 **DISCUSSION**

47
48
49 To our knowledge, this is the first systematic review and meta-analysis to evaluate the relationship
50 between meibomian gland dysfunction and primary Sjögren's syndrome dry eye. Different types of
51 design, diagnostic criteria of pSS, and various evaluation tools of MGD and DED will give a limit
52 to this study, which may restrict quality of the evidence. Yet subgroup analysis may decrease these
53 restrictions.
54
55
56
57
58
59
60

1
2
3
4 **Contributors** CZ and QH are joint first authors. CZ designed the study protocol and registered the
5 protocol on the PROSPERO database. CZ and QH drafted the manuscript. TH and YR will search,
6 select studies independently, and HY with QH will extract data and assess quality of studies
7 included. YG will be the third reviewer for study selection, data extraction and quality assessment.
8 CZ and QH revised the final study. All authors reviewed and approved the final manuscript for
9 submission.

10
11
12
13
14
15
16 **Funding** This work was supported by Science and technology development fund of Hospital of
17 Chengdu University of traditional Chinese Medicine(19LW1918MZ12).

18
19
20
21 **Competing interests** None declared.

22
23 **Patient consent for publication** Not required.

24
25 **Ethics approval** Not required.

26
27 **Provenance and peer review** Not commissioned; externally peer reviewed.

28
29 **Open access** This is an open access article distributed in accordance with the Creative Commons
30 Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix,
31 adapt, build upon this work non-commercially, and license their derivative works on different
32 terms, provided the original work is properly cited, appropriate credit is given, any changes made
33 indicated, and the use is non-commercial. See: [http://creativecommons.org/licenses/by-nc/4.](http://creativecommons.org/licenses/by-nc/4.0/)
34
35
36
37
38
39 0/.

40
41 **ORCID iD**

42 Changyan Zi <https://orcid.org/0000-0001-5369-6812>
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

- 1 Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II Definition and Classification Report. *The Ocular Surface* 2017;15:276-83.
- 2 Akpek EK, Bunya VY, Saldanha IJ. Sjögren's syndrome: more than just dry eye. *Cornea* 2019;38:658–61.
- 3 Vijmasi T, Chen FY, Chen YT, et al. Topical administration of interleukin-1 receptor antagonist as a therapy for aqueous-deficient dry eye in autoimmune disease. *Mol Vis* 2013;19:1957-65.
- 4 Liew MS, Zhang M, Kim E, et al. Prevalence and predictors of Sjögren's syndrome in a prospective cohort of patients with aqueous-deficient dry eye. *British Journal of Ophthalmology* 2012;96:1498-503.
- 5 Jung HH, Ji YS, Sung MS, et al. Long-term outcome of treatment with topical corticosteroids for severe dry eye associated with Sjögren's syndrome. *Chonnam Med J* 2015;51:26–32.
- 6 Nelson JD, Shimazaki J, Benitez-del-Castillo JM et al. The international workshop on meibomian gland dysfunction: report of the definition and classification subcommittee. *Invest Ophthalmol Vis Sci* 2011;52:1930-7.
- 7 Vehof J, Utheim TP, Bootsma H, et al. Advances, limitations and future perspectives in the diagnosis and management of dry eye in Sjögren's syndrome. *Clinical and Experimental Rheumatology* 2020;38;S301-9.
- 8 Chan TCY, Chow SSW, Wan KHN, et al. Update on the association between dry eye disease and meibomian gland dysfunction. *Hong Kong Med J* 2019;25:38-47.
- 9 Messmer EM. The pathophysiology, diagnosis, and treatment of dry eye disease. *Dtsch Arztebl Int* 2015;112:71-81.
- 10 Foulks GN, Forstot SL, Donshik PC, et al. Clinical guidelines for management of dry eye associated with Sjögren Disease. *The Ocular Surface* 2015;13:118-32.
- 11 Liang H, Kessal K, Rabut G, et al. Correlation of clinical symptoms and signs with conjunctival gene expression in primary Sjögren syndrome dry eye patients. *The Ocular Surface* 2019;17:516-25.
- 12 Menzies KL, Srinivasan S, Prokopich CL, et al. Infrared imaging of meibomian glands and

- 1
2
3
4 evaluation of the lipid layer in Sjogren's syndrome patients and nondry eye controls. *Invest*
5 *Ophthalmol Vis Sci* 2015;56:836–41.
6
7
8 13 Zang S, Cui Y, Cui Y, et al. Meibomian gland dropout in Sjögren's syndrome and non-
9 Sjögren's dry eye patients. *Eye* 2018;32:1681–7.
10
11
12 14 Wang Y, Qin Q, Liu B, et al. Clinical Analysis: Aqueous-deficient and meibomian gland
13 dysfunction in patients with primary sjogren's syndrome. *Front Med (Lausanne)* 2019;6:291.
14
15
16 15 Goto E, Matsumoto Y, Kamoi M, et al. Tear evaporation rates in Sjögren syndrome and non-
17 Sjögren dry eye patients. *Am J Ophthalmol* 2007;144:81–5.
18
19
20 16 Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and
21 meta- analysis protocols (PRISMA- P) 2015 statement. *Syst Rev* 2015;4:1.
22
23
24 17 Beckman KA, Luchs J, Milner MS. Making the diagnosis of Sjögren's syndrome in patients
25 with dry eye. *Clin Ophthalmol* 2016;10:43-53.
26
27
28 18 Yoo YS, Na KS, Kim DY, et al. Morphological evaluation for diagnosis of dry eye related to
29 meibomian gland dysfunction. *Exp Eye Res* 2017;163:72-7.
30
31
32 19 Pandis N. The chi-square test. *Am J Orthod Dentofacial Orthop* 2016;150:898-9.
33
34
35 20 Melsen WG, Bootsma MC, Rovers MM, et al. The effects of clinical and statistical
36 heterogeneity on the predictive values of results from meta-analyses. *Clin Microbiol Infect*
37 2014;20:123–9.
38
39
40 21 Debray TPA, Moons KGM, Riley RD. Detecting small-study effects and funnel plot
41 asymmetry in meta-analysis of survival data: A comparison of new and existing tests. *Res Synth*
42 *Methods* 2018;9:41-50.
43
44
45 22 Guyatt G, Oxman AD, Akl EA, et al. Grade guidelines: 1. Introduction-GRADE evidence
46 profiles and summary of findings tables. *J Clin Epidemiol* 2011;64:383–94.
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1 Flow chart and descriptions of study selection.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. Flow chart and descriptions of study selection.

210x297mm (200 x 200 DPI)

Reporting checklist for protocol of a systematic review.

Based on the PRISMA-P guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the PRISMA-Reporting guidelines, and cite them as:

Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.

			Page
		Reporting Item	Number
Title			
Identification	#1a	Identify the report as a protocol of a systematic review	page1
Update	#1b	If the protocol is for an update of a previous systematic review, identify as such	N/A

1 **Registration**
2
3

4 [#2](#) If registered, provide the name of the registry (such as page2
5
6 PROSPERO) and registration number
7
8

9
10 **Authors**
11

12
13 **Contact** [#3a](#) Provide name, institutional affiliation, e-mail address of all page1
14
15 protocol authors; provide physical mailing address of
16
17 corresponding author
18

19
20 **Contribution** [#3b](#) Describe contributions of protocol authors and identify the page 8
21
22 guarantor of the review
23
24

25
26 **Amendments**
27

28
29 [#4](#) If the protocol represents an amendment of a previously N/A
30
31 completed or published protocol, identify as such and list
32
33 changes; otherwise, state plan for documenting important
34
35 protocol amendments
36
37

38
39 **Support**
40

41
42 **Sources** [#5a](#) Indicate sources of financial or other support for the review page 8
43

44
45 **Sponsor** [#5b](#) Provide name for the review funder and / or sponsor page 8
46

47
48 **Role of sponsor or** [#5c](#) Describe roles of funder(s), sponsor(s), and / or institution(s), page 8
49
50 funder
51 if any, in developing the protocol
52

53
54 **Introduction**
55

56
57 **Rationale** [#6](#) Describe the rationale for the review in the context of what is page 3
58

1 already known

2
3
4 Objectives [#7](#) Provide an explicit statement of the question(s) the review will page 3,5
5 address with reference to participants, interventions,
6 comparators, and outcomes (PICO)
7
8
9

10 Methods

11
12
13
14 Eligibility criteria [#8](#) Specify the study characteristics (such as PICO, study design, page 4-5
15 setting, time frame) and report characteristics (such as years
16 considered, language, publication status) to be used as
17 criteria for eligibility for the review
18
19
20
21
22
23

24 Information [#9](#) Describe all intended information sources (such as electronic page 4
25 sources databases, contact with study authors, trial registers or other
26 grey literature sources) with planned dates of coverage
27
28
29
30

31
32 Search strategy [#10](#) Present draft of search strategy to be used for at least one page 4
33 electronic database, including planned limits, such that it
34 could be repeated
35
36
37
38

39 Study records - [#11a](#) Describe the mechanism(s) that will be used to manage page 5
40 data management records and data throughout the review
41
42
43

44
45 Study records - [#11b](#) State the process that will be used for selecting studies (such page 5
46 selection process as two independent reviewers) through each phase of the
47 review (that is, screening, eligibility and inclusion in meta-
48 analysis)
49
50
51
52
53

54
55 Study records - [#11c](#) Describe planned method of extracting data from reports page 5-6
56 data collection (such as piloting forms, done independently, in duplicate), any
57
58
59

1	process		processes for obtaining and confirming data from investigators	
2				
3				
4	Data items	#12	List and define all variables for which data will be sought	page 6
5			(such as PICO items, funding sources), any pre-planned data	
6			assumptions and simplifications	
7				
8				
9				
10				
11	Outcomes and	#13	List and define all outcomes for which data will be sought,	page 5
12				
13	prioritization		including prioritization of main and additional outcomes, with	
14			rationale	
15				
16				
17				
18				
19	Risk of bias in	#14	Describe anticipated methods for assessing risk of bias of	page 6
20				
21	individual studies		individual studies, including whether this will be done at the	
22			outcome or study level, or both; state how this information will	
23			be used in data synthesis	
24				
25				
26				
27				
28				
29	Data synthesis	#15a	Describe criteria under which study data will be quantitatively	page 6
30			synthesised	
31				
32				
33				
34	Data synthesis	#15b	If data are appropriate for quantitative synthesis, describe	page 6
35			planned summary measures, methods of handling data and	
36			methods of combining data from studies, including any	
37			planned exploration of consistency (such as I ² , Kendall's τ)	
38				
39				
40				
41				
42				
43				
44	Data synthesis	#15c	Describe any proposed additional analyses (such as	page 6-7
45			sensitivity or subgroup analyses, meta-regression)	
46				
47				
48				
49	Data synthesis	#15d	If quantitative synthesis is not appropriate, describe the type	page 6
50			of summary planned	
51				
52				
53				
54				
55	Meta-bias(es)	#16	Specify any planned assessment of meta-bias(es) (such as	page 7
56			publication bias across studies, selective reporting within	
57				
58				
59				
60				

studies)

1
2
3
4 Confidence in [#17](#) Describe how the strength of the body of evidence will be page 7
5
6 cumulative assessed (such as GRADE)
7
8 evidence
9

10
11 The PRISMA-P checklist is distributed under the terms of the Creative Commons Attribution License
12
13 CC-BY 4.0. This checklist was completed on 22. December 2020 using <https://www.goodreports.org/>,
14
15 a tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

BMJ Open

Meibomian gland dysfunction and primary Sjögren's syndrome dry eye: a protocol for systematic review and meta-analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-048336.R1
Article Type:	Protocol
Date Submitted by the Author:	10-Aug-2021
Complete List of Authors:	Zi, Changyan; Chengdu University of Traditional Chinese Medicine, huang, qun; Chengdu University of Traditional Chinese Medicine Affiliated Hospital, Ophthalmology Ren, Yuan; Chengdu University of Traditional Chinese Medicine Yao, Huan; Chengdu University of Traditional Chinese Medicine He, Tingting; Chengdu University of Traditional Chinese Medicine Gao, Yongxiang; Chengdu University of Traditional Chinese Medicine, drgaoyx@cdutcm.edu.cn
Primary Subject Heading:	Immunology (including allergy)
Secondary Subject Heading:	Ophthalmology
Keywords:	RHEUMATOLOGY, OPHTHALMOLOGY, Protocols & guidelines < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, IMMUNOLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4 Meibomian gland dysfunction and primary Sjögren's syndrome dry eye: a protocol
5
6 for systematic review and meta-analysis
7
8

9 Changyan Zi,MD¹, Qun Huang,MM³, Yuan Ren,MD², Huan Yao,MD², Tingting
10
11 He,MD², Yongxiang Gao,MD⁴
12
13

14
15 ¹Department of Rheumatology, Hospital of Chengdu University of Traditional Chinese
16
17 Medicine, Chengdu, 610072,China.
18

19
20
21 ² College of Clinical Medicine, Chengdu University of Traditional Chinese Medicine,
22
23 Chengdu,611137, China
24

25
26
27 ³Department of Ophthalmology, Hospital of Chengdu University of Traditional
28
29 Chinese Medicine, Chengdu, 610072,China.
30

31
32
33 ⁴College of International Education of Chengdu University of Traditional Chinese
34
35 Medicine, Chengdu, 610075,China.
36

37
38
39 Corresponding author: Yongxiang Gao, College of International Education of Chengdu
40
41 University of Traditional Chinese Medicine, No.37 Shi-er-qiao Road, Chengdu 610075,
42
43 Sichuan Province, PR China (e-mail:drgaoyx@cductcm.edu.cn)
44

45
46
47 Word count: 1289 words.
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Introduction: Primary Sjögren's syndrome (pSS) is a systematic autoimmune disorder that primarily affects exocrine glands like lacrimal and salivary glands. Dry eye disease (DED) is one of the most prevalent manifestations of pSS and usually classified into aqueous-deficient dry eye and evaporative dry eye. Sjögren's syndrome dry eye (SSDE) is generally described as aqueous-deficient dry eye. However, as leading pathophysiological mechanism of evaporative dry eye, meibomian gland dysfunction (MGD) also has influences on SSDE, which are presented in the latest studies. We speculate that SSDE is more than just aqueous-deficient dry eye. While no related systematic review and meta-analysis has been published, the present study is design to derive a better understanding of the connection between MGD and SSDE.

Methods and analysis: The Preferred Reporting items for Systematic Reviews and Meta-Analysis for Protocols (PRISMA-P) 2015 statement was used to prepare this protocol. PubMed, Embase, Web of Science, Cochrane Database, China National Knowledge Infrastructure, Wan Fang database will be searched from their inception to 31 October 2021 with restrictions of publications in English or Chinese. Two reviewers will independently carry out data extraction and quality assessment. The diagnosis of pSS will meet standard diagnostic criteria, such as ACR/EULAR or AECG. The definition of MDG and DED will differ between studies. Quality of included studies will be judged by the Newcastle-Ottawa Quality Scale (NOS). We will carry out this meta-analysis via RevMan V.5.4.1. The incidence of meibomian gland dysfunction in patients with Sjögren's syndrome dry eye will be indicated as odds ratio (OR) with 95% confidence interval (95% CI).

Ethics and dissemination: Ethical approval is not required as this meta-analysis is performed based on the published studies. The results will be published in a peer-reviewed journal.

PROSPERO registration number: CRD42021226017

Strengths and limitations of this study

- ▶ This is the first systematic review and meta-analysis to evaluate the relationship between meibomian gland dysfunction and primary Sjögren's syndrome dry eye.
- ▶ Different types of design, diagnostic criteria of pSS, and various evaluation tools of MGD and

1
2
3
4 DED will give a limit to this study, which may restrict quality of the evidence.

5
6 ▶ Subgroup analysis may decrease these restrictions.
7

8 9 **INTRODUCTION**

10
11
12 Primary Sjögren's syndrome(pSS) is a female dominated, systematic autoimmune disorder
13 characterized by a widely clinical manifestations extending from exocrine glands symptoms to
14 extraglandular involvements. As a systematic disease, multidisciplinary cooperation is required,
15 especially department of rheumatology, immunology and ophthalmology. Dry eye disease(DED) is
16 usually classified into aqueous-deficient dry eye and evaporative dry eye.¹ The mechanism of
17 Sjögren's syndrome dry eye(SSDE) currently remains unclear. In the majority of literatures, SSDE
18 is classified as aqueous-deficient dry eye, with much attention being paid to the lack of aqueous tear
19 production.²⁻⁵ However, meibomian gland dysfunction(MGD) also has been diagnosed in patients
20 with pSS.⁶
21
22
23
24
25
26
27
28
29

30
31 The International Workshop on Meibomian Gland Dysfunction defines MGD as a chronic,
32 diffuse abnormality of meibomian glands, commonly characterized by terminal duct obstruction or
33 qualitative or quantitative changes in glandular secretion.⁷ As leading pathophysiological
34 mechanism of evaporative dry eye,⁸ MGD causes a lesion to tear film lipid layer, which affects the
35 rate of tear evaporation and tear hyperosmolarity, eventually triggering onset of dry eye.⁹
36
37
38
39

40
41 Currently, proofs have been illustrated that MGD has influences on SSDE.¹⁰⁻¹³ On the basis of
42 these premises, we speculate that SSDE is more than just aqueous-deficient dry eye. In this protocol,
43 we aim to perform a comprehensive review of association between MGD and SSDE.
44
45
46
47

48 49 **METHODS**

50 51 **Registration**

52
53
54 This protocol has been registered on the PROSPERO on the 13/12/2020. The Preferred Reporting
55 items for Systematic Reviews and Meta-Analysis for Protocols(PRISMA-P) 2015 statement was
56 used to perform this protocol.¹⁴
57
58
59
60

Patient and public involvement

No patient is involved in this study.

Search strategy

PubMed, Embase, Web of Science, Cochrane Database, China National Knowledge Infrastructure, Wan Fang database will be searched from their inception to 31 October 2021 by two reviewers (TH and YR) independently. Combination of Medical Subject Headings (MeSH) and free terms will be utilized to search for potentially qualified publications (Table 1). Reference lists of original and review articles will be screened manually.

Table 1 Search strategy of PubMed
Search items
#1 “Sjogren’s Syndrome” OR “Sjogrens Syndrome” OR “Syndrome, Sjogren's” OR “Sjogren Syndrome” OR “Sicca Syndrome” OR “Syndrome, Sicca”
#2 “Meibomian Gland Dysfunction” OR “Dysfunction, Meibomian Gland” OR “Meibomian Gland Dysfunctions” OR “MG Dysfunction” OR “MG Dysfunctions”
#3 #1 AND #2
#4 “Dry Eye Syndromes” OR “Dry Eye Syndrome” OR “Dry Eye Disease” OR “Dry Eye Diseases” OR “Dry Eye” OR “Dry Eyes” OR “Evaporative Dry Eye Disease” OR “Evaporative Dry Eye Syndrome” OR “Evaporative Dry Eye” OR “Dry Eye, Evaporative” OR “Evaporative Dry Eyes”
#5 #3 AND #4

Eligibility criteria

Study design

prospective and retrospective cohort studies, case-control studies published in English or Chinese will be incorporated in this meta-analysis. In case of similar essays delivered by the same author in

1
2
3 different journals, the latest or study with the largest number of participants will be included.
4
5

6 7 Participants

8
9
10 The patients with clinical diagnosed pSS connected with dry eye and meibomian gland dysfunction
11 will be involved, regardless of age, gender and race. The diagnosis of pSS will meet AECG criteria
12 in 2002¹⁵ or ACR criteria in 2012¹⁶ or ACR/EULAR criteria in 2016.¹⁷ The diagnostic tools for DED
13 and MGD will differ between studies and be grouped into three categories: symptom questionnaires,
14
15
16
17
18 objective ocular testing and biomarkers or other emerging diagnostic techniques.¹⁸⁻¹⁹
19

20 21 Outcomes

22
23
24 The primary outcome is incident of meibomian gland dysfunction in SSDE patients. The secondary
25 outcomes mainly include the following aspects: tear-film break up time (BUT), Schirmer I test,
26
27
28 corneal fluorescein staining(CFS) and ocular surface disease index (OSDI).
29

30 31 **Study selection and data extraction**

32 33 34 Study selection

35
36
37
38 Two reviewers(TH and YR) will independently conduct study selection. Based on title and abstract,
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

52 Data extraction

53
54
55
56 The detailed data extracted in an excel spreadsheet by two researchers(HY and QH) and checked
57 for accuracy by YG are as follows: first author's name, year of publication, country of publication,
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

1
2
3
4 evaluation tools of MGD and DED, outcomes, quality assessment (Newcastle–Ottawa Scale).

5
6 Authors of primary studies will be contacted to obtain missing data.
7

8 9 **Quality assessment**

10
11
12 Quality of contained studies will be estimated by two reviewers (HY and QH) with the Newcastle-
13
14 Ottawa Quality Scale (NOS) adapted for observational studies. The scale awards 0-9 star based on
15
16 the selection, comparability and outcome(cohort) or exposure(case-control). Studies with 0-3 stars,
17
18 4-6 stars, or 7-9 stars are considered as a low-, moderate-, or high-quality. Controversies between
19
20 two reviewers will be settled by discussion or consulting YG.
21
22

23 **Data synthesis and statistical analysis**

24
25
26 At least 5 studies of same outcomes in similar populations will be pooled to perform the meta-
27
28 analysis by RevMan V.5.4.1. Otherwise, a systematic review will be implemented. For categorical
29
30 variables, the odds ratio (OR) with 95% confidence interval (CI) will be used. For continuous
31
32 variables, we will choose mean difference (MD) or standardized mean difference (SMD) with 95%
33
34 CI, depending on whether the measurement scale is consistent or not.
35
36

37 **Assessment of heterogeneity**

38
39
40 Chi-square statistic and the I^2 test are utilized to estimate the statistical heterogeneity among
41
42 included studies. $P < 0.1$ is considered as representative of statistically heterogeneity.²⁰ I^2 values of
43
44 $<25\%$, $25\%-50\%$ and $>50\%$ representing low, medium and high heterogeneity.²¹ For a significant
45
46 heterogeneity($I^2 > 50\%, P < 0.1$), a random-effect model will be selected to synthesize the data.
47
48
49 Otherwise, a fixed effect model will be used.
50
51

52 **Subgroup analysis**

53
54
55
56 Subgroup analysis is applied to high heterogeneity among publications included with following
57
58 aspects, such as diagnostic criteria for pSS, study design, different evaluation tools of MGD and
59
60 DED.

Sensitivity analysis

Eliminate literatures one by one to conduct sensitivity analysis. possible major source of heterogeneity may be found.

Assessment of publication bias

Visual assessment of the funnel plot will be applied to appraise publication bias if more than 10 articles are contained.²²

Quality of evidence

The Grading of Recommendations Assessment, Development and Evaluation(GRADE) will be used to assess the strength evidence for each outcome, which will be divided into high, moderate, low and very low level.²³

Ethics and dissemination

Ethical approval is not required since this meta-analysis is performed based on the published studies.

The results will be published in a peer-reviewed journal.

DISCUSSION

Symptoms of MGD have a significant impact on quality of life, causing not only ocular irritation, but also the sequelae of ocular surface inflammation and resultant deficits in visual function.²⁴ SSDE is a complicated disease, that needs multidisciplinary participation. More attention should be paid to MGD. To our knowledge, this is the first systematic review and meta-analysis to evaluate the relationship between meibomian gland dysfunction and primary Sjögren's syndrome dry eye. Different types of design, diagnostic criteria of pSS, and various evaluation tools of MGD and DED will give a limit to this study, which may restrict quality of the evidence. Yet subgroup analysis may decrease these restrictions.

1
2
3
4 **Contributors** CZ and QH are joint first authors. CZ designed the study protocol and registered the
5 protocol on the PROSPERO database. CZ and QH drafted the manuscript. TH and YR will search,
6 select studies independently, and HY with QH will extract data and assess quality of studies
7 included. YG will be the third reviewer for study selection, data extraction and quality assessment.
8 CZ and QH revised the final study. All authors reviewed and approved the final manuscript for
9 submission.

10
11
12
13
14
15
16 **Funding** This work was supported by Science and technology development fund of Hospital of
17 Chengdu University of traditional Chinese Medicine(19LW19、 18MZ12).

18
19
20
21 **Competing interests** None declared.

22
23 **Patient consent for publication** Not required.

24
25 **Ethics approval** Not required.

26
27 **Provenance and peer review** Not commissioned; externally peer reviewed.

28
29 **Open access** This is an open access article distributed in accordance with the Creative Commons
30 Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix,
31 adapt, build upon this work non-commercially, and license their derivative works on different
32 terms, provided the original work is properly cited, appropriate credit is given, any changes made
33 indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

34
35
36
37
38
39
40
41 **ORCID iD**

42 Changyan Zi <https://orcid.org/0000-0001-5369-6812>

REFERENCES

- 1 Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II Definition and Classification Report. *The Ocular Surface* 2017;15:276-83.
- 2 Akpek EK, Bunya VY, Saldanha IJ. Sjögren's syndrome: more than just dry eye. *Cornea* 2019;38:658–61.
- 3 Vijmasi T, Chen FY, Chen YT, et al. Topical administration of interleukin-1 receptor antagonist as a therapy for aqueous-deficient dry eye in autoimmune disease. *Mol Vis* 2013;19:1957-65.
- 4 Liew MS, Zhang M, Kim E, et al. Prevalence and predictors of Sjögren's syndrome in a prospective cohort of patients with aqueous-deficient dry eye. *British Journal of Ophthalmology* 2012;96:1498-503.
- 5 Jung HH, Ji YS, Sung MS, et al. Long-term outcome of treatment with topical corticosteroids for severe dry eye associated with Sjögren's syndrome. *Chonnam Med J* 2015;51:26–32.
- 6 Menzies KL, Srinivasan S, Prokopich CL, et al. Infrared imaging of meibomian glands and evaluation of the lipid layer in Sjögren's syndrome patients and nondry eye controls. *Invest Ophthalmol Vis Sci* 2015;56:836-41.
- 7 Nelson JD, Shimazaki J, Benitez-del-Castillo JM, et al. The international workshop on meibomian gland dysfunction: report of the definition and classification subcommittee. *Invest Ophthalmol Vis Sci* 2011;52:1930-7.
- 8 Vehof J, Utheim TP, Bootsma H, et al. Advances, limitations and future perspectives in the diagnosis and management of dry eye in Sjögren's syndrome. *Clinical and Experimental Rheumatology* 2020;38;S301-9.
- 9 Chan TCY, Chow SSW, Wan KHN, et al. Update on the association between dry eye disease and meibomian gland dysfunction. *Hong Kong Med J* 2019;25:38-47.
- 10 Shimazaki J, Goto E, Ono M, et al. Meibomian gland dysfunction in patients with Sjögren syndrome. *Ophthalmology* 1998;105:1485-8.
- 11 Zang S, Cui Y, Cui Y, et al. Meibomian gland dropout in Sjögren's syndrome and non-Sjögren's dry eye patients. *Eye* 2018;32:1681–7.
- 12 Wang Y, Qin Q, Liu B, et al. Clinical Analysis: Aqueous-deficient and meibomian gland

- dysfunction in patients with primary sjogren's syndrome. *Front Med (Lausanne)* 2019;6:291.
- 13 Goto E, Matsumoto Y, Kamoi M, et al. Tear evaporation rates in Sjögren syndrome and non-Sjögren dry eye patients. *Am J Ophthalmol* 2007;144:81–5.
- 14 Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA- P) 2015 statement. *Syst Rev* 2015;4:1.
- 15 Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. *Ann Rheum Dis* 2002;61:554-8.
- 16 Shiboski SC, Shiboski CH, Criswell L, et al. American College of Rheumatology classification criteria for Sjögren's syndrome: a data-driven, expert consensus approach in the Sjögren's International Collaborative Clinical Alliance cohort. *Arthritis Care Res (Hoboken)* 2012;64:475-87.
- 17 Shiboski CH, Shiboski SC, Seror R, et al. 2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjögren's Syndrome: A Consensus and Data-Driven Methodology Involving Three International Patient Cohorts. *Arthritis Rheumatol* 2017;69:35-45.
- 18 Beckman KA, Luchs J, Milner MS. Making the diagnosis of Sjögren's syndrome in patients with dry eye. *Clin Ophthalmol* 2015;10:43-53.
- 19 Yoo YS, Na KS, Kim DY, et al. Morphological evaluation for diagnosis of dry eye related to meibomian gland dysfunction. *Exp Eye Res* 2017;163:72-77.
- 20 Pandis N. The chi-square test. *Am J Orthod Dentofacial Orthop* 2016;150:898-9.
- 21 Melsen WG, Bootsma MC, Rovers MM, et al. The effects of clinical and statistical heterogeneity on the predictive values of results from meta-analyses. *Clin Microbiol Infect* 2014;20:123–9.
- 22 Debray TPA, Moons KGM, Riley RD. Detecting small-study effects and funnel plot asymmetry in meta-analysis of survival data: A comparison of new and existing tests. *Res Synth Methods* 2018;9:41-50.
- 23 Guyatt G, Oxman AD, Akl EA, et al. Grade guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. *J Clin Epidemiol* 2011;64:383–94.
- 24 Sabeti S, Kheirkhah A, Yin J, et al. Management of meibomian gland dysfunction: a review.

1
2
3
4 *Surv Ophthalmol* 2020;65:205-217.
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. Flow chart and descriptions of study selection.

210x297mm (200 x 200 DPI)

Reporting checklist for protocol of a systematic review.

Based on the PRISMA-P guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the PRISMA-Reporting guidelines, and cite them as:

Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.

			Page
		Reporting Item	Number
Title			
Identification	#1a	Identify the report as a protocol of a systematic review	page1
Update	#1b	If the protocol is for an update of a previous systematic review, identify as such	N/A

1 **Registration**

2

3

4 [#2](#) If registered, provide the name of the registry (such as page2

5

6 PROSPERO) and registration number

7

8

9

10 **Authors**

11

12

13 **Contact** [#3a](#) Provide name, institutional affiliation, e-mail address of all page1

14

15 protocol authors; provide physical mailing address of

16

17 corresponding author

18

19

20 **Contribution** [#3b](#) Describe contributions of protocol authors and identify the page 8

21

22 guarantor of the review

23

24

25

26 **Amendments**

27

28

29 [#4](#) If the protocol represents an amendment of a previously N/A

30

31 completed or published protocol, identify as such and list

32

33 changes; otherwise, state plan for documenting important

34

35 protocol amendments

36

37

38

39 **Support**

40

41

42 **Sources** [#5a](#) Indicate sources of financial or other support for the review page 8

43

44

45 **Sponsor** [#5b](#) Provide name for the review funder and / or sponsor page 8

46

47

48 **Role of sponsor or** [#5c](#) Describe roles of funder(s), sponsor(s), and / or institution(s), page 8

49

50 funder

51 if any, in developing the protocol

52

53

54 **Introduction**

55

56

57 **Rationale** [#6](#) Describe the rationale for the review in the context of what is page 3

58

59

60

1 already known

2
3
4 Objectives [#7](#) Provide an explicit statement of the question(s) the review will page 3,5
5 address with reference to participants, interventions,
6 comparators, and outcomes (PICO)
7

8
9
10
11 **Methods**

12
13
14 Eligibility criteria [#8](#) Specify the study characteristics (such as PICO, study design, page 4-5
15 setting, time frame) and report characteristics (such as years
16 considered, language, publication status) to be used as
17 criteria for eligibility for the review
18
19
20
21

22
23
24 Information [#9](#) Describe all intended information sources (such as electronic page 4
25 sources databases, contact with study authors, trial registers or other
26 grey literature sources) with planned dates of coverage
27
28
29

30
31
32 Search strategy [#10](#) Present draft of search strategy to be used for at least one page 4
33 electronic database, including planned limits, such that it
34 could be repeated
35
36
37

38
39 Study records - [#11a](#) Describe the mechanism(s) that will be used to manage page 5
40 data management records and data throughout the review
41
42

43
44 Study records - [#11b](#) State the process that will be used for selecting studies (such page 5
45 selection process as two independent reviewers) through each phase of the
46 review (that is, screening, eligibility and inclusion in meta-
47 analysis)
48
49
50
51

52
53
54 Study records - [#11c](#) Describe planned method of extracting data from reports page 5-6
55 data collection (such as piloting forms, done independently, in duplicate), any
56
57
58

1	process		processes for obtaining and confirming data from investigators	
2				
3				
4	Data items	#12	List and define all variables for which data will be sought	page 6
5			(such as PICO items, funding sources), any pre-planned data	
6			assumptions and simplifications	
7				
8				
9				
10				
11	Outcomes and	#13	List and define all outcomes for which data will be sought,	page 5
12				
13	prioritization		including prioritization of main and additional outcomes, with	
14			rationale	
15				
16				
17				
18				
19	Risk of bias in	#14	Describe anticipated methods for assessing risk of bias of	page 6
20				
21	individual studies		individual studies, including whether this will be done at the	
22			outcome or study level, or both; state how this information will	
23			be used in data synthesis	
24				
25				
26				
27				
28				
29	Data synthesis	#15a	Describe criteria under which study data will be quantitatively	page 6
30			synthesised	
31				
32				
33				
34	Data synthesis	#15b	If data are appropriate for quantitative synthesis, describe	page 6
35			planned summary measures, methods of handling data and	
36			methods of combining data from studies, including any	
37			planned exploration of consistency (such as I ² , Kendall's τ)	
38				
39				
40				
41				
42				
43				
44	Data synthesis	#15c	Describe any proposed additional analyses (such as	page 6-7
45			sensitivity or subgroup analyses, meta-regression)	
46				
47				
48				
49	Data synthesis	#15d	If quantitative synthesis is not appropriate, describe the type	page 6
50			of summary planned	
51				
52				
53				
54				
55	Meta-bias(es)	#16	Specify any planned assessment of meta-bias(es) (such as	page 7
56			publication bias across studies, selective reporting within	
57				
58				
59				
60				

studies)

1
2
3
4 Confidence in [#17](#) Describe how the strength of the body of evidence will be page 7
5
6 cumulative assessed (such as GRADE)
7
8 evidence
9

10
11 The PRISMA-P checklist is distributed under the terms of the Creative Commons Attribution License
12
13 CC-BY 4.0. This checklist was completed on 22. December 2020 using <https://www.goodreports.org/>,
14
15 a tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60